Floatz logo

Latozinemab

Amyotrophic Lateral Sclerosis

Alector Inc.monoclonal_antibodyPhase 2Active
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
31/ 100
Competitive Position
73/ 100

Competitive context

150 Active assets in the Amyotrophic Lateral Sclerosis cohort.

Asset / SponsorPhaseRating
TAURURSODIOL
Amylyx Pharmaceuticals Inc.
Phase 3BBB
Tofersen
Biogen
Phase 4BBB
Riluzole
AB Science
Phase 4BB
Mexiletine
Bjorn Oskarsson, MD
Phase 4BB
DIACETYL(N(4)-METHYLTHIOSEMICARBAZONATO) COPPER (II)
Collaborative Medicinal Development Pty Limited
Phase 2/3BB

View all 50 →

Same molecule, other indications

Latozinemab is also rated in:

frontotemporal dementiaDormant
B
Indicative ·
58 / 100
View asset →
neurodegenerative diseaseDormant
CCC
Indicative ·
50 / 100
View asset →
bipolar I disorderDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →